Related Experiment Video
Updated: Aug 24, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL)
Abstract:
Based on the prognostic factors obtained from our previous APL92 study, in the JALSG APL97 study, we intensified chemotherapy for patients with leukocyte counts > or = 3,000/microL and > or = 10,000/microL, also intensified consolidation chemotherapy, and then tested whether further chemotherapy is required in patients with negative RT-PCR for PML/RARalpha after the completion of consolidation therapy. Of 256 presently evaluable patients, 244 (95%) achieved CR. Predicted 5-year EFS is 67% and predicted 5-year overall survival 84%.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells
Treatment Resistent Cancers
Treatment Resistant Cancers
